LAGUNA HILLS, Calif.,
Dec. 6, 2018 /PRNewswire/
-- Prelude Corporation (PreludeDx), a leader in molecular
diagnostics and personalized medicine for early stage breast
cancer, announced today its compelling data from research on stage
1 breast cancer patients presented at the 2018 San Antonio Breast
Cancer Symposium in San Antonio,
TX. The data shows that PreludeDx's newly-developed
assay can stratify risk of local recurrence in stage 1 breast
cancer patients.
The study data shared by Dr. Troy
Bremer, Chief Scientific Officer of PreludeDx, demonstrated
that the new test was able to stratify patients where those in the
low risk group had a 6% local 10-yr invasive recurrence risk with
surgery alone or surgery and radiation therapy. Patients in the
elevated risk group had a 49% risk of local invasive recurrence
when treated with surgery alone but had a substantial benefit from
radiation therapy.
As outcomes for early stage breast cancer patients improve, the
oncology community has asked for more specific data on local
control as they move from looking at distant metastases to local
recurrence risk. One surprising finding was that elevated risk
patients with surgery alone had nearly a 50% chance of developing
invasive breast cancer in 10 years and still had a substantial
recurrence risk of 31% with adjuvant radiation therapy. "This
research represents a first step toward incorporating biomarker
findings to inform local-regional management," said Pat Whitworth, MD, Director of Nashville Breast
Center and Chief Science Officer of TME Breast Care Network. "This
new test from PreludeDx promises to add 10-year local control
information to 10-year distant metastasis-free survival when
doctors consider tumor biology and management for an individual
patient."
Daniel Forche, PreludeDx
President and CEO stated "Our mission at PreludeDx is to improve
the lives of early stage breast cancer patients. Following the
success of DCISionRT for DCIS patients, we are very pleased with
these research efforts to develop a new assay that can provide
additional refinement of treatment for stage 1 breast cancer
patients. These results will be expanded to the full data set that
includes over 500 patients. We look forward to sharing the complete
results at one of the premier oncology symposia in 2019 with
additional clinical validations to follow."
About DCISionRT for Breast DCIS
DCISionRT is the only
risk assessment test for patients with ductal carcinoma in situ
(DCIS) that predicts radiation therapy benefit. In the US, over
60,000 women are newly diagnosed with DCIS each year. The test was
developed by PreludeDx and built on research that began with
funding from the National Cancer Institute to better understand the
biology of DCIS. DCISionRT assesses a woman's individual tumor
biology along with other risk factors to provide a personalized
recurrence risk. The test provides a Decision ScoreTM that
identifies a woman's risk as low or elevated. DCISionRT's
intelligent reporting provides a woman's recurrence risk after
breast conserving surgery alone and with the addition of radiation
therapy. In turn, this new information may help patients and their
physicians to make more informed treatment decisions.
About PreludeDx
PreludeDx is a leading personalized
breast cancer diagnostics company dedicated to serving breast
cancer patients and physicians worldwide. Founded in 2009 with
technology licensed from University of
California San Francisco, PreludeDx has focused on
developing precision breast cancer tools that will impact a
patient's treatment decision. Our mission is to provide patients
and physicians with innovative technologies that improve patient
outcomes and reduce the overall cost burden to the healthcare
system. Before making a treatment decision, Know Your
Risk™.
For more information on how PreludeDx is making a difference for
patients, please visit the Company's website:
www.preludedx.com and follow us on Twitter @PreludeDx,
Facebook and LinkedIn.
PreludeDx, the PreludeDx logo, DCISionRT, the DCISionRT logo,
Decision Score, The DCIS Test, Know Your Risk, Know Her Risk, and
Your Biology, Your Decision are trademarks of Prelude Corporation
or its wholly owned subsidiaries in the
United States and foreign countries.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/preludedx-presents-promising-research-in-stage-1-breast-cancer-patients-at-the-2018-san-antonio-breast-cancer-symposium-300761504.html
SOURCE PreludeDx